Bill > AB259

This bill establishes new regulations for prescription drug pricing in Nevada, focusing on limiting drug prices to the "maximum fair price" established by the federal Medicare program. Specifically, the bill prohibits entities from purchasing or seeking reimbursement for certain prescription drugs at prices higher than the maximum fair price set by the U.S. Secretary of Health and Human Services. Violations of these pricing restrictions will be considered a deceptive trade practice, allowing aggrieved parties to bring civil actions for consumer fraud. The bill exempts certain health coverage providers but allows them to voluntarily opt into the regulations. The legislation was motivated by concerns about high prescription drug costs in the United States, which disproportionately affect uninsured and underinsured patients and contribute to increased healthcare and insurance expenses. The provisions will take effect on January 1, 2026, and will not apply to existing drug sale or reimbursement contracts until their renewal or extension. The bill aims to protect Nevada residents from excessive drug prices by providing a legal mechanism to enforce more affordable prescription drug pricing.